Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06352281RecruitingPhase 1/Phase 2
CAR-T cell therapy for chronic or hard-to-treat ITP
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Kunming, YunnanAges 8–75 - NCT06287398RecruitingPhase 2
Epcoritamab and chemo before stem cell transplant for relapsed large B-cell lymphoma
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Melbourne, VictoriaAges 18 years+ - NCT06111612Recruiting
Intensive chemo before stem cell transplant for myeloid cancers with spread outside marrow
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06513234RecruitingPhase 2
Orelabrutinib and Obinutuzumab for untreated marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and obinutuzumab, for people with a type of slow-growing lymphoma called marginal zone lymphoma who have not had any previous treatment. The goal is to see if this combination can shrink or control the cancer with manageable side effects.
TianjinAges 18 years+ - NCT04014374Recruiting
Safety study for stem cell transplant after mogamulizumab
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
Milwaukee, WisconsinAges 18 years+ - NCT06517004RecruitingPhase 1
Study of JWCAR201 for relapsed or refractory large B-cell lymphoma
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
ShanghaiAges 18 years+ - NCT05219903Recruiting
Study of children with eosinophilic gut disorders
This study looks at children ages 0–18 with eosinophilic gut disorders (EGIDs) to better understand these conditions and how they are managed. It may help doctors improve care by comparing real-world information from patients followed at participating hospitals.
PaviaAges birth–18 years - NCT07798427Enrolling by invitation
Ultrasound-guided IV placement study
This study compares two ways to place an IV (a small tube that gives you medicine or fluids through a vein). One method uses ultrasound to find the best vein, the other uses the traditional method. It aims to see if ultrasound helps make IV placement easier and more successful.
New York, New YorkAges 12 years+ - NCT06521255RecruitingPhase 3
New drug combo vs standard for relapsed DLBCL
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
BeijingAges 18 years+ - NCT06520176RecruitingPhase 3
Comparing two stem cell collection methods for multiple myeloma
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
Dongyang, ZhejiangAges 18–75 - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT07800234Recruiting
Egyptian registry for hemophagocytic lymphohistiocytosis
This study creates a national registry in Egypt to collect information about people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages the body's own tissues. The goal is to learn more about the disease and improve care.
CairoAges Up to 18 years - NCT07794514Recruiting
Comparing two drugs for liver graft-versus-host disease
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
Hangzhou, ZhejiangAges 12 years+ - NCT07793006Recruiting
New ways to diagnose lymphoma and castleman disease
This study tests new methods to diagnose lymphoma and multicentric castleman disease, which are conditions that can affect people with HIV. It may help find these diseases earlier and more accurately.
LilongweAges 1 year+ - NCT07800247Recruiting
Sickle cell disease registry for young patients
This study collects information about children, teens, and young adults with sickle cell disease to better understand the condition in Egypt. It may help improve care and treatments for people with sickle cell disease.
CairoAges Up to 39 years - NCT06478472Recruiting
Orelabrutinib plus rituximab for marginal zone lymphoma
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Xiamen, FujianAges 18 years+ - NCT05874674Recruiting
Testing nafamostat to reduce bleeding risk during dialysis
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
Wŏnju, KangwondoAges 18–99 - NCT06524726Recruiting
PNH registry for people with confirmed PNH
This is a long-term registry study for people with a confirmed diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). It simply collects information over time to better understand the condition and how it's managed. There is no experimental treatment involved.
Altamonte Springs, FloridaAges Any age - NCT06526065Recruiting
Understanding lymphoma biology to improve treatment
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
Göttingen, Lower SaxonyAges 18–85 - NCT06508099RecruitingPhase 2
Vitamin A and D supplements after stem cell transplant
This trial tests whether taking vitamin A and D after a stem cell transplant can help improve recovery. It is for people with certain blood cancers who have a matched donor and are in remission or have low disease activity.
Saint PetersburgAges 18 years+ - NCT06532084RecruitingPhase 2
Sorafenib to prevent relapse after stem cell transplant
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Saint PetersburgAges 18–75 - NCT06271252RecruitingPhase 1
Study of OriCAR-017 for relapsed or refractory multiple myeloma
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Atlanta, GeorgiaAges 18–75 - NCT06536010Recruiting
Testing a new combination therapy for AML
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Huai'an, JiangsuAges 18–75 - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.